Michele Ciboddo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michele Ciboddo has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
- Shannon Elisabeth Elf
The University of Utah
38 shared publications - Nicole Arellano
The University of Utah
37 shared publications - Chufan Cai
Ben May Department for Cancer Research, University of Chicago
31 shared publications - Freya Q. Zhang
Department of Medicine, The University of Chicago, Chicago, IL, USA
31 shared publications - Hao Fan
Department of Medicine, The University of Chicago, Chicago, IL 60637, USA
31 shared publications - Jeronimo Najarro
Section of Hematology and Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois
31 shared publications
Latest Publications
- Open Access
Selective scoring of drug effects in multicellular co-culture systems
Multicellular co-culture screening reveals compound effects that depend on cell-cell interactions. Standard dose-response metrics fail to resolve effects that arise either from target-effector cell interactions or from non-specific toxic effects. Here, we developed Co-culture Efficacy Score (CES), a robust computational framework that enables systematic identification of compounds that selectively modulate cellular interactions in multicellular assays. CES framework supports both therapeutic scoring that penalizes direct effector cell toxicity, as well as a mechanistic discovery that estimates immunomodulatory effects by adjusting for effector cell responses. When screening 527 compounds across 10 hematological cancer models co-cultured with natural killer (NK) cells, CES distinguished co-culture-specific immunomodulatory effects from NK cell toxicity and cancer cell inhibitory responses, recovering systematic enhancer and inhibitory patterns. We further assessed CES robustness using higher-resolution validation screens and demonstrated its applicability to identify selective compounds in anti-CD19 CAR T-cell and antiviral host-pathogen screens. To facilitate its broad use, we implemented CES as an interactive web-application for quantitative analysis of compound responses in co-culture assays, providing a widely applicable scoring framework for cancer immunotherapy, antiviral screening and drug discovery.
Open AccessSelective scoring of drug effects in multicellular co-culture systems
Multicellular co-culture screening reveals compound effects that depend on cell-cell interactions. Standard dose-response metrics fail to resolve effects that arise either from target-effector cell interactions or from non-specific toxic effects. Here, we developed Co-culture Efficacy Score (CES), a robust computational framework that enables systematic identification of compounds that selectively modulate cellular interactions in multicellular assays. CES framework supports both therapeutic scoring that penalizes direct effector cell toxicity, as well as a mechanistic discovery that estimates immunomodulatory effects by adjusting for effector cell responses. When screening 527 compounds across 10 hematological cancer models co-cultured with natural killer (NK) cells, CES distinguished co-culture-specific immunomodulatory effects from NK cell toxicity and cancer cell inhibitory responses, recovering systematic enhancer and inhibitory patterns. We further assessed CES robustness using higher-resolution validation screens and demonstrated its applicability to identify selective compounds in anti-CD19 CAR T-cell and antiviral host-pathogen screens. To facilitate its broad use, we implemented CES as an interactive web-application for quantitative analysis of compound responses in co-culture assays, providing a widely applicable scoring framework for cancer immunotherapy, antiviral screening and drug discovery.
- 21 August 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (8) , 971-983
Type 2 calreticulin mutations activate ATF6 to promote BCL-xL–mediated survival in myeloproliferative neoplasms
Most calreticulin (CALR) mutations in myeloproliferative neoplasms are classified as either type 1, a 52–base pair deletion (CALRdel52); or type 2, a 5–base pair insertion (CALRins5). Both are gain-of-function (GOF) mutations that generate an identical mutant C-terminal tail, which mediates the binding to, and activation of, the thrombopoietin receptor myeloproliferative leukemia protein (MPL). We recently reported that despite this shared GOF, CALRdel52 but not CALRins5 mutations cause loss of calcium binding function, leading to activation of, and dependency on, the inositol-requiring enzyme 1/X-box binding protein 1 pathway of the unfolded protein response (UPR). This led us to ask whether CALRins5 mutations activate and depend on a different UPR pathway, and whether this is likewise mediated by a mutation type–specific loss-of-function (LOF). Here, we show that CALRins5 mutations lead to activation of the activating transcription factor 6 (ATF6) pathway of the UPR due to loss of CALR chaperone function. This LOF is caused by interference of the CALRins5 mutant C terminus with key chaperone residue H170. Furthermore, we show that CALRins5 cells are partially dependent on ATF6 for cytokine-independent growth, and identify B-cell lymphoma extra large as a transcriptional target of ATF6 that promotes type 2 CALR-mutant cell survival.
- 21 August 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (8) , 971-983
Type 2 calreticulin mutations activate ATF6 to promote BCL-xL–mediated survival in myeloproliferative neoplasms
Most calreticulin (CALR) mutations in myeloproliferative neoplasms are classified as either type 1, a 52–base pair deletion (CALRdel52); or type 2, a 5–base pair insertion (CALRins5). Both are gain-of-function (GOF) mutations that generate an identical mutant C-terminal tail, which mediates the binding to, and activation of, the thrombopoietin receptor myeloproliferative leukemia protein (MPL). We recently reported that despite this shared GOF, CALRdel52 but not CALRins5 mutations cause loss of calcium binding function, leading to activation of, and dependency on, the inositol-requiring enzyme 1/X-box binding protein 1 pathway of the unfolded protein response (UPR). This led us to ask whether CALRins5 mutations activate and depend on a different UPR pathway, and whether this is likewise mediated by a mutation type–specific loss-of-function (LOF). Here, we show that CALRins5 mutations lead to activation of the activating transcription factor 6 (ATF6) pathway of the UPR due to loss of CALR chaperone function. This LOF is caused by interference of the CALRins5 mutant C terminus with key chaperone residue H170. Furthermore, we show that CALRins5 cells are partially dependent on ATF6 for cytokine-independent growth, and identify B-cell lymphoma extra large as a transcriptional target of ATF6 that promotes type 2 CALR-mutant cell survival.
- Open Access
- 2 April 2024
- Published by American Association for Cancer Research (AACR)
Figure S8 from NRAS Mutant Dictates AHCYL1-Governed ER Calcium Homeostasis for Melanoma Tumor Growth
Supplementary Figure 8. AHCYL1 deficiency causes cell growth attenuation, ER calcium decrease, and apoptosis in NRAS-Q61K overexpressed Mel-ST cells.
- 2 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from NRAS Mutant Dictates AHCYL1-Governed ER Calcium Homeostasis for Melanoma Tumor Growth
Supplementary Figure 8. AHCYL1 deficiency causes cell growth attenuation, ER calcium decrease, and apoptosis in NRAS-Q61K overexpressed Mel-ST cells.
- Open Access
- 2 April 2024
- Published by American Association for Cancer Research (AACR)
Table S1 from NRAS Mutant Dictates AHCYL1-Governed ER Calcium Homeostasis for Melanoma Tumor Growth
Supplemental Table 1. Transcription factor scan. Transcription factors candidates for AHCYL1 transcription were generated based on reported binding response elements that can match AHCYL1 promoter region sequence.
- 2 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from NRAS Mutant Dictates AHCYL1-Governed ER Calcium Homeostasis for Melanoma Tumor Growth
Supplemental Table 1. Transcription factor scan. Transcription factors candidates for AHCYL1 transcription were generated based on reported binding response elements that can match AHCYL1 promoter region sequence.
- Open Access
- 2 April 2024
- Published by American Association for Cancer Research (AACR)
Figure S5 from NRAS Mutant Dictates AHCYL1-Governed ER Calcium Homeostasis for Melanoma Tumor Growth
Supplementary Figure 5. IP3R deficiency doesn’t change AHCYL1 protein level in the whole cell lysates.
- 2 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from NRAS Mutant Dictates AHCYL1-Governed ER Calcium Homeostasis for Melanoma Tumor Growth
Supplementary Figure 5. IP3R deficiency doesn’t change AHCYL1 protein level in the whole cell lysates.
- Open Access
- 2 April 2024
- Published by American Association for Cancer Research (AACR)
Figure S3 from NRAS Mutant Dictates AHCYL1-Governed ER Calcium Homeostasis for Melanoma Tumor Growth
Supplementary Figure 3. AHCYL2 does not overexpress and is not critical in human NRAS-mutated melanoma as AHCYL1.
- 2 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from NRAS Mutant Dictates AHCYL1-Governed ER Calcium Homeostasis for Melanoma Tumor Growth
Supplementary Figure 3. AHCYL2 does not overexpress and is not critical in human NRAS-mutated melanoma as AHCYL1.
- Open Access
- 2 April 2024
- Published by American Association for Cancer Research (AACR)
Figure S10 from NRAS Mutant Dictates AHCYL1-Governed ER Calcium Homeostasis for Melanoma Tumor Growth
Supplementary Figure 10. CREB doesn’t positively regulate AHCYL1 transcription.
- 2 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from NRAS Mutant Dictates AHCYL1-Governed ER Calcium Homeostasis for Melanoma Tumor Growth
Supplementary Figure 10. CREB doesn’t positively regulate AHCYL1 transcription.
- Open Access
- 2 April 2024
- Published by American Association for Cancer Research (AACR)
Table S1 from NRAS Mutant Dictates AHCYL1-Governed ER Calcium Homeostasis for Melanoma Tumor Growth
Supplemental Table 1. Transcription factor scan. Transcription factors candidates for AHCYL1 transcription were generated based on reported binding response elements that can match AHCYL1 promoter region sequence.
- 2 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from NRAS Mutant Dictates AHCYL1-Governed ER Calcium Homeostasis for Melanoma Tumor Growth
Supplemental Table 1. Transcription factor scan. Transcription factors candidates for AHCYL1 transcription were generated based on reported binding response elements that can match AHCYL1 promoter region sequence.
- Open Access
- 2 April 2024
- Published by American Association for Cancer Research (AACR)
Figure S11 from NRAS Mutant Dictates AHCYL1-Governed ER Calcium Homeostasis for Melanoma Tumor Growth
Supplementary Figure 11. There is positive correlation between ATF2 and AHCYL1 mRNA levels in human cutaneous melanoma patients by TCGA analysis.
- 2 April 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S11 from NRAS Mutant Dictates AHCYL1-Governed ER Calcium Homeostasis for Melanoma Tumor Growth
Supplementary Figure 11. There is positive correlation between ATF2 and AHCYL1 mRNA levels in human cutaneous melanoma patients by TCGA analysis.